fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Multivitamins

All products: not a benefit

Pregnancy Multivitamin · DIN 02535718 · · tablet

Off-Formulary Interchangeable, not an ODB benefitDormant since August 3, 2026 · checked October 5, 2026 · What does dormant mean?
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
1 brand, same coverage
Pregnancy Multivitamin · DIN 02535718 Manufacturer: Jamp Pharma Corporation; listing date 2025-02-28 Health Canada: Dormant since 2026-08-03 · brand PREGNANCY MULTIVITAMIN · ATC B03AE04 IRON, MULTIVITAMINS AND MINERALS · form Tablet · route Oral · ingredients VITAMIN E (DL-ALPHA TOCOPHERYL ACETATE) 13.8 MG, VITAMIN B6 (PYRIDOXINE HYDROCHLORIDE) 10 MG, VITAMIN B12 (CYANOCOBALAMIN) 12 MCG, BETA-CAROTENE 1.6 MG, NICOTINAMIDE 20 MG, D-PANTOTHENIC ACID (CALCIUM PANTOTHENATE) 5 MG, CALCIUM (CALCIUM CARBONATE) 300 MG, IODINE (POTASSIUM IODIDE) 0.15 MG, VITAMIN B2 (RIBOFLAVIN) 3.4 MG, ASCORBIC ACID (ASCORBIC ACID) 120 MG, VITAMIN B1 (THIAMINE MONONITRATE) 3 MG, MAGNESIUM (MAGNESIUM OXIDE) 50 MG, IRON (FERROUS FUMARATE) 35 MG, ZINC (ZINC OXIDE) 15 MG, COPPER (COPPER GLUCONATE) 2 MG, FOLIC ACID 1.1 MG, VITAMIN D3 (CHOLECALCIFEROL) 600 UNIT · company Jamp pharma corporation · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02535718)

Source record
DIN 02535718: Pregnancy Multivitamin Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 882800066; group id 889; item number 2136; lccId None; manufacturer id JPC Source form: Tab; strength: None Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $0.3125; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02535718 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102454
Interchangeable products
Pregvit · DIN 02451573 · not recorded
Shortage status: active shortage (reported December 2, 2024, estimated to end December 31, 2026, last updated September 15, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02535718
Shortage record checked October 6, 2026
Health Canada lists this DIN as Dormant since August 3, 2026 — choose a marketed DIN from the same-category list.
Other drugs in the same formulary class (88:28 Multivitamins) and how they are covered

Matched class: 88:28 Multivitamins

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: MULTIVITAMINS FOR INFUSION 88:28 Multivitamins

MULTIVITAMINS FOR INFUSION

· 2 products · General benefit · strengths: · Inj-2x5mL Vial Pk, Inj-4mL+1mL Vial Pk Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 88:28
Full class listing Related classes: 88:08 Vitamin B, 88:12 Vitamin C, 88:16 Vitamin D Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
Product monograph unavailable: no marketed product found

Availability

Pregnancy Multivitamin · DIN 02535718 Shortage status: active shortage (reported 2024-12-02, estimated to end 2026-12-31, last updated 2026-09-15); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02535718

Check this DIN again
Health Canada: dormant products
Health Canada defines dormant products as: “products that were previously marketed in Canada but for which the manufacturer has suspended sale for period of at least 12 months.” (canada.ca, September 10, 2026 ↗)

Other review policies

For Pregnancy Multivitamin: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026